- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04300829
Cicaderma Efficacy vs Standard Care of Sites in Preventing Radiodermatitis in Non-metastatic Breast Cancer Patients (CICA-RT)
Randomised Multicentric Phase III Study Evaluating the Efficacy of Cicaderma vs Standard Management of Each Site in Preventing Radiodermatitis After Adjuvant Post-operative Breast Irradiation in Patients With Non-metastatic Breast Cancer
Study Overview
Status
Intervention / Treatment
Detailed Description
Breast cancer is the most common cancer in women. It accounts for more than 1/3 of new cancer cases and is the 1st cause of death for women.
Management usually includes tumorectomy or mastectomy precede or not by a chemotherapy, then adjuvant irradiation that can be supplemented with adjuvant chemotherapy and / or hormone therapy.
Radiotherapy uses ionizing radiation (photons, electrons ...) to destroy cancer cells and consists in precisely directing these radiations on the area to be treated while preserving as much as possible healthy tissues and surrounding organs.
Radiation-induced dermatitis is a skin lesion that occurs after exposure to ionizing radiation and is commonly seen in patients. Acute radiodermatitis occurs in the days or weeks following the start of irradiation with different degrees of severity (dry or exsudative radiodermatitis, acute radionecrosis) They are responsible for an alteration of patients' quality of life (pain, sensitivity to UV radiation, discomfort sensations ...), which may lead to a temporary or even permanent therapeutic interruption and reduce the probability of tumor control.
The management of these dermatitis is very heterogeneous, no study having demonstrated the superiority of a preventive or curative treatment. Trolamine (Biafine®) is to date the only topic with a Marketing Authorization (MA) for the treatment of radiation-induced secondary erythema.
A study conducted on 254 patients at the Léon Bérard Center from 1999 to 2001 demonstrated that the preventive use of a calendula-based topical was associated with a statistically significant reduction of grade 2 radiodermitis compared to trolamine in patients presenting an early breast cancer treated with post-operative irradiation. However, this calendula ointment, which does not have the MA in the indicated indication, was in practice more difficult to apply than trolamine.
Currently, skin hygiene measures to be applied are systematically explained to patients before carrying out post-operative radiotherapy (cotton clothing, neutral soap, etc.). Some centers such as Center Léon Bérard recommend the systematic use of a topic after each session, while others recommend hygiene measures or implement other options (essential oils ...). However, the effectiveness of these current practices on the prevention of radiodermatitis has not yet been demonstrated.
It is a phase III, prospective, interventional, multicentric, comparative, randomized, open study with 2 parallel arms Patients will be randomized (1 :1) in Arm A (hygiene measures + preventive treatment with Cicaderma ointment) or Arm B (preventive treatment according to the site recommendations (at least the hygiene measures) with a stratification (site, body mass index ≤25 vs >25 and RT hypofractionning).
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Séverine METZGER
- Phone Number: +33 4.78.78.27.86
- Email: severine.metzger@lyon.unicancer.fr
Study Locations
-
-
-
Avignon, France, 84000
- Recruiting
- Institut Sainte-Catherine
-
Paris, France, 75005
- Recruiting
- Institut Curie
-
Contact:
- Youlia KIROVA, MD PhD
- Email: youlia.kirova@curie.fr
-
Saint-Cloud, France, 92210
- Not yet recruiting
- Institut Curie
-
Contact:
- Youlia KIROVA, MD
- Email: youlia.kirova@curie.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥18 years
- Patient requiring a post-operative radiotherapy (post mastectomy or tumorectomy) for a mammary adenocarcinoma or an unilateral in situ breast cancer histologically documented, early stage of disease (non metastatic)
- Patient with no residual tumor (R0 or R1)
- Patient informed and having given her signed consent
- Patient affiliated to a social security regimen
Exclusion Criteria:
- Unsolved cutaneous toxicities of any previous treatment
- Hormonotherapy started prior to radiotherapy
- Concomitant use of other topical treatments than the study treatments on the irradiated area
- Patient treated by concomitant chemotherapy and/or targeted therapy
- Known hypersensibility to at least one component of the topicals used or Cicadema ointment
- Patient for whom follow-up does not seem possible even in the short term
- Pregnant or breastfeeding woman
- Participation in another clinical trial that may interfere with the evaluation of the primary endpoint
- Patient Under tutorship or curatorship or deprived of liberty
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Simple hygiene rules of the site + Cicaderma ointment
Hygiene rules (use of a neutral soap, no bath, use of non-alcoholic products, delicate drying of the skin, wearing of cotton clothing) and Cicaderma ointment application)
|
Cicaderma ointment (2 applications / day: after the radiotherapy session) and in the evening) + simple hygiene rules
Other Names:
|
Active Comparator: Preventive standard cares
Preventive standard cares of the site including hygiene rules (use of a neutral soap, no bath, use of non-alcoholic products, delicate drying of the skin, wearing of cotton clothing) and a maximum of one topical treatment
|
Simple hygiene rules according to the site recommandations including eventually a maximum of one topical treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of the Cicaderma ointment efficacy versus the standard management of each site in preventing the onset of grade >= 2 radiodermatitis (NCI-CTCAE-V5)
Time Frame: Up to 30+/-4 days after the end of radiotherapy interruption
|
Number of patients presenting >= 2 radiodermatitis according to the National Cancer Institute - Common Terminology Criteria for Adverse Events-Version (NCI-CTCAE-V5)
|
Up to 30+/-4 days after the end of radiotherapy interruption
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patients' satisfaction
Time Frame: 30+/-4 days after the end of radiotherapy interruption
|
Patients' satisfaction evaluated using the "Patient's evaluation of the preventive management of radiodermatits" - Likert scale in 5 points (from very unsatisfied to very satisfied)
|
30+/-4 days after the end of radiotherapy interruption
|
Patients' quality of life: DLQI questionnaire
Time Frame: Up to 30+/-4 days after the end of radiotherapy interruption
|
Patients' quality of life evaluated using the Dermatology Life Quality Index (DLQI) questionnaire (validated questionnaire composed of 10 items leading to a global score)
|
Up to 30+/-4 days after the end of radiotherapy interruption
|
Patients' pain in the irradiated area: numeric scale
Time Frame: Up to 30+/-4 days after the end of radiotherapy interruption
|
Patients' pain evaluated using a numeric scale from 0 (no pain) to 10 (unbearable pain)
|
Up to 30+/-4 days after the end of radiotherapy interruption
|
Rate of temporary or permanent RT interruption related to the onset of grade 3 radiodermatitis
Time Frame: Through radiotherapy completion, an average of 5 weeks
|
Temporary or permanent radiotherapy interruption related to the onset of grade 3 radiodermatitis observed during patients' treatment period
|
Through radiotherapy completion, an average of 5 weeks
|
Rate of prurit onset whatever the grade
Time Frame: Up to 30+/-4 days after the end of radiotherapy interruption
|
Prurit onset whatever the grade observed
|
Up to 30+/-4 days after the end of radiotherapy interruption
|
Doses of radiation therapy received
Time Frame: Through radiotherapy completion, an average of 5 weeks
|
Doses of radiation therapy received during each radiotherapy session
|
Through radiotherapy completion, an average of 5 weeks
|
Delay of onset of the first cutaneous event (radiodermatitis or prurit) grade ≥2
Time Frame: Up to 30+/-4 days after the end of radiotherapy
|
Onset of the first grade >= 2 cutaneous event (radiodermatitis or prurit)
|
Up to 30+/-4 days after the end of radiotherapy
|
Compliance with the Cicaderma ointment application (experimental arm)
Time Frame: Up to 30+/-4 days after the end of radiotherapy
|
Compliance evaluated according to the ointment tubes brought back by the patients (not used or partially used) and patient's diary
|
Up to 30+/-4 days after the end of radiotherapy
|
Determination of the factors measured prior to treatment initiation which are associated to the onset of grade ≥2 radiodermatitis (cup size)
Time Frame: At inclusion
|
Cup size
|
At inclusion
|
Determination of the factors measured prior to treatment initiation which are associated to the onset of grade ≥2 radiodermatitis (phototype)
Time Frame: At inclusion
|
Phototype
|
At inclusion
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Séverine RACADOT, MD, Centre Leon Bérard
- Principal Investigator: Youlia KIROVA, MD PhD, Institut Curie
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ET19-084 - CICA-RT
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Radiation Toxicity
-
University of Milano BicoccaRecruiting
-
Essentia HealthCompleted
-
Centre Francois Baclesse, LuxembourgBIONEXT; NEOLYS DIAGNOSTICS - ALARA GROUPNot yet recruitingCancer | Radiation Toxicity | Radiosensitivity
-
UNC Lineberger Comprehensive Cancer CenterRecruitingToxicity | Radiation ToxicityUnited States
-
Duke UniversityCompletedChemotherapeutic Toxicity | Radiation Therapy ComplicationUnited States
-
Shandong Cancer Hospital and InstituteUnknownAdvanced Cancer | Radiation Toxicity | RadiosensitivityChina
-
NeolysCentre Francois Baclesse; Centre Hospitalier Universitaire de CaenNot yet recruitingPediatric Cancer | Radiation Toxicity | Radiosensitivity
-
Mayo ClinicCompletedQuality of Life | Cancer | Radiation Toxicity | Relaxation During Radiation TherapyUnited States
-
Jules Bordet InstituteNot yet recruitingRadiation Toxicity | Radiodermatitis | Radiotherapy Side Effect
Clinical Trials on cicaderma + simple hygiene rules
-
Università degli Studi 'G. d'Annunzio' Chieti e...S. Spirito Hospital, Pescara, ItalyCompletedSleep Apnea Syndromes | Sleep DisorderItaly
-
The University of Hong KongRecruiting